Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 3/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.52 |
| ▸ | LTB4R | Q15722 | 7/20 | 0.50 |
| ▸ | PPARA | Q07869 | 5/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.40 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | RECQL | P46063 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31001655 | 0.96 | CYP4F2 (0.49) | CYP4F2CYP4A11LTB4RPPARAPIN1 | |
| SCHEMBL26018932 | 0.92 | CYP4F2 (0.57) | CYP4F2CYP4A11LTB4RPPARAPIN1 | |
| SCHEMBL29422928 | 0.90 | CYP4F2 (0.54) | CYP4F2CYP4A11PPARAPIN1PPARG | |
| SCHEMBL22922053 | 0.90 | CYP4F2 (0.54) | CYP4F2CYP4A11PPARAPIN1PPARG | |
| SCHEMBL25996671 | 0.86 | CYP4F2 (0.51) | CYP4F2CYP4A11LTB4RPPARAPIN1 | |
| SCHEMBL22921301 | 0.86 | LTB4R (0.60) | LTB4RPPARA | |
| SCHEMBL22921511 | 0.86 | LTB4R (0.60) | LTB4RPPARA | |
| SCHEMBL22921548 | 0.86 | LTB4R (0.60) | LTB4RPPARA | |
| SCHEMBL25996444 | 0.86 | LTB4R (0.60) | LTB4RPPARA | |
| SCHEMBL26067305 | 0.85 | CYP4F2 (0.50) | CYP4F2CYP4A11LTB4RPPARAPIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114126593-A | Functionalized long chain hydrocarbon mono-and dicarboxylic acids useful for preventing or treating disease | 埃斯佩尔维塔治疗股份有限公司 | 2022-03-01 | — | — | CN | disclosed |